CTA
REGN icon

Chesley Taft & Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Chesley Taft & Associates’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$274K Buy
439
+2
+0.5% +$1.36K 0.01% 332
2026
Q1 		$338K Sell
437
-800
-65% -$612K 0.01% 310
2025
Q4 		$955K Buy
1,237
+802
+184% +$545K 0.04% 224
2025
Q3 		$245K Hold
435
– – 0.01% 326
2025
Q2 		$228K Sell
435
-50
-10% -$27.9K 0.01% 324
2025
Q1 		$308K Hold
485
– – 0.01% 290
2024
Q4 		$345K Hold
485
– – 0.02% 278
2024
Q3 		$510K Hold
485
– – 0.02% 247
2024
Q2 		$510K Hold
485
– – 0.03% 242
2024
Q1 		$467K Hold
485
– – 0.02% 246
2023
Q4 		$426K Hold
485
– – 0.02% 254
2023
Q3 		$399K Hold
485
– – 0.03% 242
2023
Q2 		$348K Hold
485
– – 0.02% 253
2023
Q1 		$399K Hold
485
– – 0.03% 238
2022
Q4 		$350K Hold
485
– – 0.02% 246
2022
Q3 		$334K Sell
485
-574
-54% -$361K 0.02% 246
2022
Q2 		$626K Buy
1,059
+30
+3% +$19.5K 0.04% 208
2022
Q1 		$737K Hold
1,029
– – 0.04% 209
2021
Q4 		$650K Buy
1,029
+106
+11% +$65.2K 0.03% 215
2021
Q3 		$559K Hold
923
– – 0.03% 223
2021
Q2 		$516K Sell
923
-55
-6% -$27.9K 0.03% 231
2021
Q1 		$474K Sell
978
-195
-17% -$94.9K 0.03% 226
2020
Q4 		$567K Hold
1,173
– – 0.04% 206
2020
Q3 		$657K Sell
1,173
-300
-20% -$182K 0.05% 185
2020
Q2 		$919K Hold
1,473
– – 0.07% 161
2020
Q1 		$719K Buy
1,473
+50
+4% +$20.6K 0.07% 163
2019
Q4 		$534K Sell
1,423
-32
-2% -$10.8K 0.04% 205
2019
Q3 		$404K Buy
1,455
+177
+14% +$52.4K 0.03% 218
2019
Q2 		$400K Sell
1,278
-2,537
-67% -$845K 0.03% 216
2019
Q1 		$1.57M Sell
3,815
-37
-1% -$15.2K 0.13% 125
2018
Q4 		$1.44M Sell
3,852
-544
-12% -$199K 0.14% 126
2018
Q3 		$1.78M Hold
4,396
– – 0.14% 127
2018
Q2 		$1.52M Sell
4,396
-130
-3% -$40.7K 0.13% 132
2018
Q1 		$1.56M Sell
4,526
-74
-2% -$25.7K 0.14% 132
2017
Q4 		$1.73M Hold
4,600
– – 0.15% 132
2017
Q3 		$2.06M Sell
4,600
-25
-0.5% -$11.9K 0.18% 116
2017
Q2 		$2.27M Hold
4,625
– – 0.21% 104
2017
Q1 		$1.79M Hold
4,625
– – 0.17% 117
2016
Q4 		$1.7M Sell
4,625
-146
-3% -$55.5K 0.17% 115
2016
Q3 		$1.92M Sell
4,771
-233
-5% -$93.5K 0.19% 103
2016
Q2 		$1.75M Hold
5,004
– – 0.18% 111
2016
Q1 		$1.8M Sell
5,004
-4,745
-49% -$1.96M 0.19% 104
2015
Q4 		$5.29M Sell
9,749
-1,173
-11% -$636K 0.56% 60
2015
Q3 		$5.08M Sell
10,922
-609
-5% -$327K 0.55% 59
2015
Q2 		$5.88M Sell
11,531
-1,380
-11% -$673K 0.6% 57
2015
Q1 		$5.83M Hold
12,911
– – 0.6% 58
2014
Q4 		$5.3M Hold
12,911
– – 0.54% 63
2014
Q3 		$4.66M Sell
12,911
-400
-3% -$134K 0.49% 66
2014
Q2 		$3.76M Sell
13,311
-39
-0.3% -$11.6K 0.39% 79
2014
Q1 		$4.01M Sell
13,350
-50
-0.4% -$15.4K 0.43% 74
2013
Q4 		$3.69M Sell
13,400
-156
-1% -$44.9K 0.37% 81
2013
Q3 		$4.24M Sell
13,556
-9,612
-41% -$2.53M 0.46% 74
2013
Q2 		$5.21M Buy
+23,168
New +$5.39M 0.6% 57

Other funds holding REGN

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return
HCM
Howland Capital Management Boston, Massachusetts $2.77B AUM 19.56% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Chesley Taft & Associates's REGN Position: Q2 2026 in Review

Chesley Taft & Associates increased its Regeneron Pharmaceuticals (REGN) stake by 0.46% in Q2 2026, buying an estimated $1.36K and bringing the position to 439 shares worth $274K. The position accounts for 0.01% of the portfolio, ranked #332.

Chesley Taft & Associates first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $5.88M in Q2 2015. 208 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Chesley Taft & Associates held 439 shares of Regeneron Pharmaceuticals worth $274K as of Q2 2026.
  • Chesley Taft & Associates bought 2 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.36K.
  • Regeneron Pharmaceuticals made up 0.01% of Chesley Taft & Associates's portfolio in Q2 2026, its #332 holding.
  • Chesley Taft & Associates first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Chesley Taft & Associates's Regeneron Pharmaceuticals position peaked at $5.88M in Q2 2015.
  • 208 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Chesley Taft & Associates's 13F filing for Q2 2026, filed 8 Jul 2026.